IGC Pharma furnished an updated investor presentation highlighting CALMA Phase 2 progress, interim blinded pooled data and potential valuation inflection.
Key Highlights:
- Furnished an updated investor presentation (Exhibit 99.1) to be used with investors, analysts and partners.
- CALMA Phase 2 trial: 146 target participants, >80% have completed dosing; near-term catalysts are enrollment completion and topline readout.
- Blinded pooled CALMA data (n≈104) show LS mean CMAI change −13.6 at week 2 and −14.9 at week 6; cannot establish treatment effect.
- Interim (n=26) comparisons suggest IGC-AD1 may show earlier/larger changes vs published brexpiprazole data and reduced sleep disturbance (71% week 2, 78% week 6; p-values reported).
- Company highlights IP portfolio and illustrative valuation scenarios: current market cap ~ $30M with potential post‑Phase 2 scenarios up to $350–$750M (illustrative, not projections).
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.